Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Posting of Circular & Notice of GM

October 11, 2024
RNS Number : 9446H Renalytix PLC 11 October 2024   Renalytix plc (" Renalytix " or the " Company ")   Posting of Circular and Notice of General Meeting   LONDON and NEW YORK , 11 October, 2024   ̶   Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics

Director/PDMR Shareholding

October 11, 2024
RNS Number : 7887H Renalytix PLC 11 October 2024     Renalytix plc ("Renalytix" or the "Company")   Director/PDMR Dealing   LONDON and NEW YORK , 11 October 2024   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing

Holding(s) in Company

October 11, 2024
RNS Number : 7886H Renalytix PLC 11 October 2024   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non- UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3.

Holding(s) in Company

October 11, 2024
RNS Number : 7884H Renalytix PLC 11 October 2024   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non- UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3.

Holding(s) in Company

October 9, 2024
RNS Number : 5976H Renalytix PLC 09 October 2024   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing

Admission of Shares & Total Voting Rights

October 8, 2024
RNS Number : 4004H Renalytix PLC 08 October 2024   Renalytix plc (" Renalytix " or the " Company ")   Admission of Shares & Total Voting Rights   Renalytix (AIM: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to

Commencement of trading on OTCQB in the United States

October 8, 2024
Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024 LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro

Commencement of trading on OTCQB in the US

October 8, 2024
RNS Number : 3346H Renalytix PLC 08 October 2024     Renalytix plc ("Renalytix" or the "Company")   Commencement of trading on OTCQB in the United States   Renalytix plc American Depository Shares (ADSs) begin trading on   OTCQB Venture Market under symbol "RNLXY" effective from Market Open on

Result of Placing and Subscription

October 1, 2024
RNS Number : 4887G Renalytix PLC 01 October 2024   THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (TOGETHER THIS "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE

Audited US GAAP financial results

October 1, 2024
RNS Number : 4130G Renalytix PLC 01 October 2024     Renalytix plc ("Renalytix" or the "Company")   Audited US GAAP financial results for the fiscal year ended 30 June 2024   LONDON and NEW YORK , 1 October, 2024   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in
Displaying 1 - 10 of 605